



CooperVision Unveils New clariti® 1 Day Multifocal Contact Lens, Affirming Commitment to Brand Innovation

ROCHESTER, N.Y., August 1, 2024—Affirming its commitment to continuous innovation across its leading silicone hydrogel 1-day product families, CooperVision today announced the new clariti® 1 day multifocal with Binocular Progressive System™ contact lenses. The upgraded lenses feature several next-generation enhancements to provide better vision¹ and high levels of comfort^{2,3} for presbyopic patients, and an easy and successful fitting experience⁴ for eye care professionals (ECPs).

The product will debut in the United States this summer, with availability in other markets across the globe beginning in late 2024 and 2025.

“Year after year, clariti® 1 day multifocal has been a popular choice among ECPs for presbyopes who need crisp vision⁵ and good comfort⁶ at a great value⁷. Through our deep expertise in multifocal optics and fitting, we saw an opportunity to take a great product and make it even better. Applying some of our latest innovations—including the same lens design introduced in the highly regarded MyDay® multifocal⁷—elevates the performance of clariti® 1 day multifocal and, ultimately, ECP and wearer satisfaction^{†8},” said Simon Seshadri, Senior Vice President, Global Marketing & Life Cycle Management, CooperVision.

The new clariti® 1 day multifocal with Binocular Progressive System™ maintains the features that ECPs and wearers know and love about the lens^{9,10}, then incorporates CooperVision’s advanced 3 Add multifocal system for improved visual acuity at all distances plus an upgraded edge design for increased comfort. CooperVision Binocular Progressive System®—the innovative technology originally developed for the widely adopted MyDay® multifocal prescription with two pairs of lenses or less.^{11,12,13} contact lenses⁷—also provides a streamlined fitting process to make it easier for practitioners to fit patients with the right lens from the start¹¹. In a clinical study, a remarkable 98% of patients were fit with their final prescription with two pairs of lenses or less.^{11,12,13}

The full family of clariti® 1 day lenses—sphere, toric, and multifocal—offer all-day comfort and feature great handling¹⁴ and high oxygen transmissibility¹⁵ (up to 3x the Dk/t of some hydrogel 1-day toric lenses), which allows for 100 percent corneal oxygen consumption to help maintain ocular health.[‡]

For more information, visit <https://coopervision.com/practitioner/our-products/clariti-1-day-family/clariti-1-day-multifocal>.

* After 2 weeks of daily wear.

† Subject rating overall comfort on a typical day at 2-week visit.

‡ Based on manufacturers published data (up to 3X sphere and multifocal) and Lumb E. & Symons A. Comparison of Dk/t values of daily disposable soft toric contact lenses using high resolution thickness profiling. BCLA Poster presentation at NCC 2016 (up to 2X toric).

References

1 CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add; with ratings from 85 to 89 out of 100; n=90 habitual MFCL wearers.

2 CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add with a rating of 88 out of 100; n=90 habitual MFCL wearers.

3 CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add; with a rating of 93 out of 100; n=90 habitual MFCL wearers.

4 CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add; n=90.

5 CVI data on file, 2019. Prospective, bilateral, subject-masked dispensing study with clariti® 1 day multifocal. N=48 habitual soft MFCL wearers at 2 sites in North America, at baseline.

6 CVI data on file, 2022. Verve Online Brand Survey with ECPs who recommend somofilcon A for new wearers in U.S., Spain, Italy, UK and Korea. n=249 (90% strongly agree/agree).

7 CVI data on file, 2022.

8 CVI data on file, 2022. Prospective, crossover, bilateral, subject masked, daily wear, dispensing study (4 clinical sites in U.S.) (n=58 habitual soft MFCL wearers).

9 CVI data on file, 2019. Prospective, bilateral, subject-masked dispensing study with clariti® 1 day multifocal. N=48 habitual soft MFCL wearers at 2 sites in North America. *At baseline approximately 5 mins after lens insertion.

10 CooperVision data on file, 2019. clariti® 1 day Wearer Experience Survey conducted online in U.S., n=298: sphere, toric or multifocal; habitual FRP, DD, and new wearers who purchased clariti® 1 day; strongly or somewhat agree.

11 CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add; n=90 habitual MFCL wearers.

12 CVI data on file 2020. Prospective, double-masked, bilateral, one-week dispensing study UK with MyDay® multifocal; n=104 habitual multifocal contact lens wearers.

13 CVI data on file 2021. Prospective, subject-masked, randomized, bilateral, two-week dispensing study at 5 US sites with MyDay® multifocal; n=58 habitual multifocal contact lens wearers.

14 CVI data on file 2019. Multi-visit study to assess handling performance and dehydration characteristics for 4 DD CLs in 20 CL wearers.

15 Brennan NA. Beyond Flux: Total Corneal Oxygen Consumption as an Index of Corneal Oxygenation During Contact Lens Wear. *Optom Vis Sci.* 2005;82(6):467-472.

###

About CooperVision

CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women's health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 including, among others, statements regarding a product launch and features and technologies that may impact demand for new products. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to research and development, regulatory requirements, clinical studies, sales, marketing, and distribution plans and capabilities; potential product performance and quality issues; intellectual property risks; competition; and other factors described in CooperCompanies' Securities and Exchange Commission filings, including the "Business", "Risk Factors" and

"Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in Cooper's Annual Report on Form 10-K for the fiscal year ended October 31, 2023, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company's analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.

Media Contact

Heather Kowalczyk, APR

McDougall Communications for CooperVision

heather@mcdougallpr.com or 585-434-2148